← Human Trials & Peer-Reviewed Studies
Efficacy of Insulin Like Growth Factor-1(IGF-1) on Bone Regeneration in Intrabony Defects : A Clinico-radiograph Study
Plain-language guide to NCT06426524: not phased non-randomized trial of IGF-1 LR3, 24 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06426524
- Phase
- not phased
- Status
- status unknown
- Start
- 2023-05-19
- Completion (planned or actual)
- 2024-05
- Participants
- 24 (estimated)
- Design
- non-randomized, open label (everyone knows who gets what), treatment
- Conditions studied
- Intrabony Periodontal Defect
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
This registered not phased trial tested IGF-1 LR3.
It had two arms (groups): Test group (experimental) and Control group (active comparator).
In test group, after reflection of flap and degranulation, IGF-1 gel with hydroxyapatite will be placed in the defect and sutures will be placed.
In control group, after reflection of flap and degranulation, hydroxyapatite will be placed in the defect and sutures will be placed.
The registry classes the interventions as procedure.
More on the Plan
In test group, after reflection of flap and degranulation, IGF-1 gel with hydroxyapatite will be placed in the defect and sutures will be placed.
In control group, after reflection of flap and degranulation, hydroxyapatite will be placed in the defect and sutures will be placed.
Who Took Part
Enrollment: 24 planned participants were the target.
It was open to people of any sex aged from 18 years with no upper age limit.
Healthy volunteers could join, not only people with the condition.
How the Study Was Run
Design: non-randomized, parallel-group and open-label.
Groups ran in parallel: each of the participants stayed in one arm throughout.
Being open-label, the IGF-1 LR3 study did not mask who received what.
It started in 2023-05-19 with completion listed for 2024-05.
It ran at 1 site in India.
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Bone Regeneration (time frame: 3 months and 6 months). clinical attachment level (time frame: 3 months and 6 months). Probig depth (time frame: 3 months and 6 months).
It also tracked 1 secondary outcome, for example Plaque Index.
What This Means in Plain Language
Put simply, this is a not phased, non-randomized trial of IGF-1 LR3 in 24 people.
Its size is small, so on its own it can only give an early look.
Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.